share_log

bluebird bio | 4: Statement of changes in beneficial ownership of securities-Officer Obenshain Andrew

bluebird bio | 4：持股變動聲明-高管 Obenshain Andrew

SEC announcement ·  01/09 13:00
牛牛AI助理已提取核心訊息
Andrew Obenshain, President and CEO of bluebird bio, Inc., completed a sale of 3,162 shares of common stock on January 5, 2024. The transaction was carried out on the open market with the shares sold at a price of $1.4294 each, resulting in a total sale value of approximately $4,519.76. Following the sale, Obenshain's direct holdings in the company amount to 287,972 shares of common stock.
Andrew Obenshain, President and CEO of bluebird bio, Inc., completed a sale of 3,162 shares of common stock on January 5, 2024. The transaction was carried out on the open market with the shares sold at a price of $1.4294 each, resulting in a total sale value of approximately $4,519.76. Following the sale, Obenshain's direct holdings in the company amount to 287,972 shares of common stock.
藍鳥生物公司總裁兼首席執行官安德魯·奧本沙因於2024年1月5日完成了3,162股普通股的出售。該交易在公開市場上進行，股票以每股1.4294美元的價格出售，總銷售價值約爲4519.76美元。出售後，Obenshain在該公司的直接持有量爲287,972股普通股。
藍鳥生物公司總裁兼首席執行官安德魯·奧本沙因於2024年1月5日完成了3,162股普通股的出售。該交易在公開市場上進行，股票以每股1.4294美元的價格出售，總銷售價值約爲4519.76美元。出售後，Obenshain在該公司的直接持有量爲287,972股普通股。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。